Cargando…
Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment
SIMPLE SUMMARY: Many drugs has become available for the advanced hepatocellular carcinoma and sequential systemic therapies play an important role in the clinical settings. Because the key eligibility criteria for post-progression treatment included the performance status of ≦1 and Child-Pugh score...
Autores principales: | Hatanaka, Takeshi, Kakizaki, Satoru, Nagashima, Tamon, Namikawa, Masashi, Ueno, Takashi, Tojima, Hiroki, Takizawa, Daichi, Naganuma, Atsushi, Arai, Hirotaka, Sato, Ken, Harimoto, Norifumi, Shirabe, Ken, Uraoka, Toshio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601832/ https://www.ncbi.nlm.nih.gov/pubmed/33050527 http://dx.doi.org/10.3390/cancers12102906 |
Ejemplares similares
-
Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately
por: Tojima, Hiroki, et al.
Publicado: (2021) -
Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct‐acting antivirals
por: Takakusagi, Satoshi, et al.
Publicado: (2021) -
Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study
por: Hatanaka, Takeshi, et al.
Publicado: (2019) -
Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021) -
Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)